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A Phase II Trial of Carboplatin/Vinorelbine with
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Advanced Non-small Cell Lung Cancer
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Introduction: The impact of chemotherapy dose delivery has not
been well studied in patients with non-small cell lung cancer
(NSCLC). Overlapping hematologic toxicities commonly limit
planned dose intensity of combination chemotherapy regimens. A
phase II study investigating carboplatin and vinorelbine, supported
by pegfilgrastim, in the treatment of patients with advanced NSCLC
was performed.
Methods: Chemotherapy-naı¨ve patients with locally advanced or
metastatic NSCLC were treated with carboplatin area under the
curve (AUC) 6 mg/ml per minute intravenously on day 1 and
vinorelbine 30 mg/m2 intravenously on days 1 and 8 every 3 weeks
for four planned cycles. Pegfilgrastim was administered on day 9 of
each cycle as a 6-mg subcutaneous injection. The primary endpoint
was incidence of cycle 1 febrile neutropenia. Secondary endpoints
included incidence of grade 3/4 hematologic and nonhematologic
toxicities, delivered dose intensity, and overall survival.
Results: Thirty patients (21 men, 9 women) with a median age of 61
years (range, 43–79) were enrolled. Of 120 planned patient cycles,
101 (84%) were completed. There was one episode of cycle 1 febrile
neutropenia. Overall response rate was 27%. Median dose delivered
for vinorelbine was 17.2 mg/m2 per week, representing a delivered
dose intensity of 86%. Median survival was 9.4 months (95%
confidence interval: 6.1–18.0) with a 3-year survival rate of 20%.
Conclusions: This regimen of carboplatin and vinorelbine with
pegfilgrastim support was associated with a low rate of febrile
neutropenia and good maintenance of planned dose intensity. Al-
though response and survival are similar to other chemotherapy
regimens in advanced NSCLC, studies optimizing chemotherapy
delivery in this setting may help inform treatment approaches in
patients with earlier stage disease.
Key Words: Dose intensity, Growth factors, Cytokines, Lung can-
cer, Febrile neutropenia.
(J Thorac Oncol. 2007;2: 520–525)
Lung cancer is the leading cause of cancer-related mortalityin both men and women in the United States. In 2007, an
estimated 213,380 new lung cancer diagnoses will be made
with an estimated 160,390 deaths.1 Despite a variety of new
chemotherapeutic agents introduced over the past 20 years,
overall survival rates remain poor. As a result, novel strate-
gies are needed to improve long-term patient outcomes.
Vinorelbine, a semisynthetic vinca alkaloid, has shown
significant activity in advanced non-small cell lung cancer
(NSCLC), both as a single agent and in combination with
cisplatin.2,3 As a result of its activity in advanced disease and
favorable side effect profile, its role in the adjuvant setting
has additionally been explored in a number of phase III trials,
including the recently reported Adjuvant Navelbine Interna-
tional Trialist Association (ANITA) and JBR.10 trials.4–6
Maintaining dose intensity with standard weekly vinorelbine
dosing schedules, however, can be challenging. In the large
European prospective randomized phase III trial identifying
cisplatin and vinorelbine as a standard treatment regimen for
advanced NSCLC, dose intensity was limited to 71% for
vinorelbine primarily because of neutropenia.3
Debate exists between the use of cisplatin and carbo-
platin in the treatment of patients with NSCLC. A recent
individual patient data meta-analysis (CISCA) demonstrated
statistically significant higher response rates (33% versus
26%) for cisplatin-containing regimens with an odds ratio of
1.37 (95% CI: 1.16–1.62, p  0.001) compared with carbo-
platin-containing regimens.7 Although carboplatin was asso-
ciated with a slightly increased risk of death (hazard ratio:
1.07; 95% CI: 0.99–1.15, p  0.101), these results were not
statistically significant. Subgroup analyses suggest that cis-
platin has a significant survival advantage when combined
with third-generation agents.
Carboplatin has been shown to have a more favorable
side effect profile in a number of randomized phase II and III
trials.8–12 As a result, it is commonly substituted for cisplatin
in the advanced lung cancer setting but is associated with
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increased myelosuppression. Carboplatin in combination
with vinorelbine has been explored in a number of phase II
NSCLC trials.13–20 Although generally well tolerated, dose-
limiting myelosuppression, as a result of overlapping hema-
tologic toxicities, may limit on-time chemotherapy delivery
and has led to studies incorporating myeloid growth factor
support.21
Pegfilgrastim is a polyethylene glycol modified form of
filgrastim designed to have a decreased plasma clearance
allowing for longer half-life and a reduced dosing schedule.
Randomized phase II and III trials has previously shown that
pegfilgrastim produces similar neutrophil recovery counts
with chemotherapy treatment compared with standard daily
filgrastim alone with similar safety profiles.22–24 Based on
these observations, a phase II study was performed investi-
gating the ability of pegfilgrastim to maintain the dose inten-
sity of carboplatin and vinorelbine in patients with advanced
lung cancer.
PATIENTS AND METHODS
Patients with previously untreated locally advanced
(stage III) or metastatic (stage IV) NSCLC were eligible for
enrollment. Limited radiation therapy exposure was allowed.
The study was designed as a phase II, single-arm, nonran-
domized, open-label clinical trial. Pegfilgrastim was provided
by Amgen, Inc. Carboplatin and vinorelbine were provided
by commercial sources. Additional eligibility criteria in-
cluded age older than 18 years, the presence of measurable or
assessable disease, performance status (PS) 0–2 with a life
expectancy of 6 months or more, and adequate hematologic
parameters including absolute neutrophil count (ANC)
greater than 1.5  109/liter and platelet count greater than
100  109/liter. Exclusion criteria included previous treat-
ment with chemotherapy, symptomatic brain metastases, ac-
tive additional malignancy, known human immunodeficiency
virus infection, lithium or cytokines within 2 weeks of study
entry, other investigational agents, active pregnancy, or known
sensitivity to Escherichia coli–derived drug preparations.
Four planned cycles of carboplatin area AUC 6 mg/ml
per minute intravenously on day 1 and vinorelbine 30 mg/m2
intravenously on days 1 and 8 were administered every 21
days. Chemotherapy cycles were discontinued for disease
progression. Pegfilgrastim was administered as a single 6-mg
injection subcutaneously on day 9, approximately 24 hours
after completion of day 8 vinorelbine infusion. Complete
blood counts (CBCs) were performed weekly throughout the
study period (days 1, 8, and 15 of each 21-day cycle).
The primary endpoint of the study was the occurrence
of febrile neutropenia (defined as ANC less than 0.5 
109/liter with a temperature of 38.2°C) during cycle 1. Sec-
ondary endpoints included the number of grade 3/4 hemato-
logic and nonhematologic toxicities across all cycles. Addi-
tional outcomes of interest included delivered dose intensity,
treatment response, and overall survival.
Response criteria were based on bidimensional mea-
surements from measurable and assessable lesions. Complete
response (CR) was defined as the disappearance of all mea-
surable or assessable disease without the development of new
lesions. Partial response (PR) was defined as more than 50%
reduction in the sum of the products of two perpendicular
diameters of measurable disease without the development of
new lesions. Stable disease (SD) for measurable lesions was
defined as less than 50% reduction or less than 25% increase
in the sum of the products of two perpendicular diameters of
measurable lesions that persist for more than 8 weeks without
development of any new lesions. For assessable lesions, SD
was defined as no clear-cut change in tumor size that lasts
more than 8 weeks without development of any new lesions.
Progressive disease (PD) for measurable lesions was defined
as an increase in the product of two perpendicular diameters
of any measured lesion by 25% over the size present on study
entry or at the point of greatest response. For assessable
lesions, a definite increase in tumor size or the appearance of
new lesions was defined PD. New osseous or central nervous
system lesions were defined as PD.
The sample size goal was 30 patients. If the true rate of
febrile neutropenia is 21%, then there was a 16% chance of
observing a febrile neutropenia rate that exceeded 31% and a
less than 4% chance of observing a rate that exceeded 36%
(10%–15% higher than the 21% rate observed in the phase I
pegfilgrastim study).24 An exact 95% binomial confidence
interval (CI) was calculated for the proportion of patients
experiencing febrile neutropenia during cycle 1. The overall
response rate, defined as the proportion of patients with a CR
and PR, and the disease control rate, defined as the proportion
of patients with a CR, PR, and SD were estimated, along with
a 95% CI. The Kaplan-Meier product-limit estimator was
used to describe patient survival. Survival time was defined
as the time between initiation of treatment and death or last
follow-up.
Hematologic and nonhematologic toxicity assessments
and grading were performed using the Common Toxicity
Criteria version 2.0 and assessed over 12 weeks of treatment.
Dose adjustments were made according to the system show-
ing the greatest degree of toxicity. Chemotherapy was held
for grade 3/4 nonhematologic toxicities and resumed after
toxicity decreased to grade 1. No treatment course began until
all treatment-related adverse events from the previous course
had resolved to grade 1. Treatment was then resumed with a
25% dose reduction for remaining cycles.
Chemotherapy was delayed weekly for an ANC less
than 1.5  109/liter and/or a platelet count less than 100 
109/liter on day 1 of each cycle. Reductions in both carbo-
platin and vinorelbine by 25% were performed for all subse-
quent cycles for an episode of febrile neutropenia, defined as
temperature of 38.2ºC or higher with an ANC less than 500
109/liter during a cycle. The day 8 vinorelbine dose was
reduced by 50% for all subsequent cycles for an ANC 1.0 to
1.5  109/liter and deleted for an ANC less than 1.0 
109/liter.
Vinorelbine dosing was held for bilirubin more than 1.8
mg/dl at the start of a cycle. Delays of more than 14 days
resulted in removal from the study. Dose reductions by 25%
for all subsequent cycles were performed for an episode of
grade 2 neurotoxicity and discontinued altogether for grade
3/4 neurotoxicity.
Journal of Thoracic Oncology • Volume 2, Number 6, June 2007 Pegfilgrastim to Support Chemotherapy in Advanced Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung Cancer 521
The protocol was approved by the Duke University
Medical Center Institutional Review Board and carried out in
accordance with the Declaration of Helsinki, U.S. Food and
Drug Administration Good Clinical Practices, and local eth-
ical and legal requirements.
RESULTS
Thirty patients (21 men, 9 women) with a PS of 2 or
less and a median age 61 years (range, 43–79) were enrolled
between August 2002 and April 2003. Patient characteristics
are summarized in Table 1. Median baseline hematologic
parameters included hemoglobin 12.6g/dL (range, 9.3–15.2
g/dl), platelets 283  109/liter (range, 119–792  109/liter),
and ANC 5.6  109/liter (range, 2.6–18.2  109/liter).
Results are shown in Table 2. A total of 101 of 120
planned patient cycles (84%) were completed for an average
of 3.2 cycles per patient (range, one to four cycles). The
median dose intensity for vinorelbine was 17.2 mg/m2 per
week with a delivered dose intensity of 86%. There was one
episode (3%) of cycle 1 grade 4 febrile neutropenia (95% CI:
0.08–17.22) and one additional episode of grade 3 febrile
neutropenia noted across all patient cycles. Hematologic
toxicities included three grade 3 anemias, three grade 3
thrombocytopenias, five grade 3 neutropenias, one grade 4
thrombocytopenia, and six grade 4 neutropenias. Thirteen
dose reductions were required for 12 patients; six hemato-
logic toxicities (four grade 2 neutropenias, one grade 3
neutropenia, one grade 4 neutropenia), and seven nonhema-
tologic toxicities. Omission of the day 8 vinorelbine, across
all cycles, was required in seven patients: two for hemato-
logic toxicity (one grade 3 neutropenia, one grade 4 neutro-
penia) and five for nonhematologic toxicities. Dose delays
were required in a total of 10 patients: three for hematologic
toxicity (one grade 1 thrombocytopenia, one grade 1 and 2
thrombocytopenia in separate cycles, one grade 2 thrombo-
cytopenia), and seven for nonhematologic toxicities. Five
patients required dose reduction or omission of vinorelbine
on day 8 across all cycles because of neutropenia before
pegfilgrastim administration. Across all patient cycles, me-
dian hematologic nadirs include hemoglobin 10.9g/dl, plate-
lets 130  109/liter, and ANC 3.2  109/liter.
Overall response rate was 27% (95% CI: 12–46) with
a disease control rate of 67% (95% CI: 47–83). Disease
response included eight (27%) with PR, 12 (40%) with SD,
and seven (23%) with PD. Three patients (10%) received
only one cycle of chemotherapy and were not assessable for
response. Of the three nonassessable patients who received
one cycle of chemotherapy; one died of complications of
radiation pneumonitis before receiving cycle 2, a second
patient developed cycle 1 grade 4 febrile neutropenia and
desired no additional treatment, and a third developed a grade
4 nontreatment-related adverse event after cycle 1 and was
removed from the protocol. All patients were included in the
TABLE 1. Baseline Patient Characteristics (n  30)
Patient Characteristics Results
Median age, yr (range) 61 (43–79)
Gender, no. (%)
Male 21 (70)
Female 9 (30)
Race, no. (%)
African American 4 (13)
White 26 (87)
Histology, no. (%)
NSCLC 30 (100)
Median baseline hematologic parameters,
109/liter (range)
Absolute neutrophil count 5.6 (2.6–18.2)
Hemoglobin 12.6 (9.3–15.2)
Platelets 283 (119–792)
Stage, no. (%)
IIIA 2 (7)
IIIB 7 (23)
IV 21 (70)
Performance status, no. (%)
0 5 (17)
1 25 (83)
NSCLC, non-small cell lung cancer.
TABLE 2. Results
Outcome Measure Patient (n  30)
Patient cycles
Completed/planned, no. (%) 101/120 (84)
Average per patient, no. (range) 3.3 (1–4)
Febrile neutropenia, no. (%)
Cycle 1 1 (3)
Cycles 2–4 1 (3)
Hematologic toxicity, no. (%)
Grade 3
Anemia 3 (10)
Neutropenia 5 (17)
Thrombocytopenia 3 (10)
Grade 4
Anemia 0 (0)
Neutropenia 6 (20)
Thrombocytopenia 1 (3)
Dose reductions, no. (%)
Hematologic toxicity 6 (20)
Nonhematologic toxicity 7 (23)
Response, no. (%)
Complete response 0 (0)
Partial response 8 (27)
Stable disease 12 (40)
Progressive disease 7 (23)
Not assessable (off after 1 cycle) 3 (10)
Overall survival
Median survival, mo, no. (95% CI) 9.4 (6.1–18.0)
6-mo survival, % (95% CI) 67 (52–86)
1-yr survival, % (95% CI) 43 (29–65)
2-yr survival, % (95% CI) 27 (15–48)
3-yr survival, % (95% CI) 20 (10–41)
CI, confidence interval.
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survival analysis. Five of 30 patients remain alive 43 to 48
months after initiation of protocol treatment. Median survival
(Figure 1) is estimated at 9.4 months (95% CI: 6.1–18).
Sixty-seven percent of patients were alive at 6 months (95%
CI: 0.52–0.86), 43% at 1 year (95% CI: 0.29–0.65), 27% at
2 years (95% CI: 0.15–0.48), and 20% at 3 years (95% CI:
0.10–0.41).
DISCUSSION
Neutropenia is a limiting factor in the administration of
chemotherapy and is the most common dose-limiting toxici-
ty.25 However, the relationship of hematologic toxicity or
dose delivery to outcome in NSCLC has not been well
explored. A recent landmark analysis of three randomized
NCSLC trials (GEMVIN, ELVIS, MILES) was performed.26
GEMVIN randomly assigned 501 patients with stage IIIB
(effusion or supraclavicular nodes) or stage IV NSCLC,
younger than 70 years, to cisplatin-vinorelbine or cisplatin-
gemcitabine compared with gemcitabine-vinorelbine.27 EL-
VIS randomized 191 stage IIIB/IV NSCLC patients older
than age 70 to best supportive care or vinorelbine days 1 and
8 every 3 weeks up to six cycles.28 MILES randomized 698
patients aged 70 years and older with stage IIIB/IV NSCLC
to receive vinorelbine, gemcitabine, or the combination.29
The landmark trial revealed a hazard ratio for death of 0.65
(95% CI: 0.46–0.93) for those with severe chemotherapy-
induced neutropenia and 0.74 (95% CI: 0.56–0.98) for those
with mild neutropenia.26 Statistically significant increases in
median survival were additionally noted for those with either
moderate or severe chemotherapy-induced neutropenia
compared with those without neutropenia. The authors
theorize that neutropenia is a pharmacodynamic measure
of in vivo dose delivery that correlates with improved
clinical outcomes.
The introduction of myeloid growth factors, such as
filgrastim, have improved dose delivery of chemotherapy
while reducing neutropenia, infection, antibiotic use, and
hospitalization.25,30 Pegfilgrastim is a modified formulation of
filgrastim in which a 20-kDa polyethylene glycol molecule
is bound at the amino terminus. Pegfilgrastim clearance is
attributed to granulocyte colony–stimulating factor receptor–
mediated clearance and is ANC dependent.
Three phase III clinical trials have been reported and
published to date on the efficacy of pegfilgrastim in support-
ing breast cancer patients receiving myelosuppressive che-
motherapy.22,23,31 Green et al.22 reported data on a 6-mg fixed
dose of pegfilgrastim administered approximately 24 hours
after the end of the chemotherapy infusion. Holmes et al.23
reported data on a single injection of pegfilgrastim 100 g/kg
administered approximately 24 hours after completion of the
chemotherapy infusion. Both studies included a control arm
of filgrastim 5 g/kg per day and demonstrated that a single
dose of pegfilgrastim (100 g/kg or 6-mg) effectively en-
hanced postchemotherapy neutrophil recovery in a manner
similar to that of daily filgrastim. In addition, both groups of
authors reported the safety profiles to be similar. Vogel et
al.31 recently reported data on patients randomized to receive
placebo or pegfilgrastim 6-mg subcutaneously on day 2 of
each 21-day cycle after receiving docetaxel 100 mg/m2 in-
travenously. Patients receiving pegfilgrastim had statistically
significant lower incidence rates of febrile neutropenia, fe-
brile neutropenia–related hospitalizations, and use of intrave-
nous antiobiotics. Additional studies in breast cancer have
documented the ability to increase dose intensity by reducing
the interval between treatments with growth factor sup-
port.32–36 These dose-dense strategies have been associated
with improved survival in the adjuvant setting.34
Studies exploring the importance of planned dose de-
livery or dose density in NSCLC have been more limited and
complicated by the myelosuppressive drugs commonly used
in combination regimens. For example, with overlapping
hematologic toxicities, the timely administration of carbopla-
tin in combination with vinorelbine may be compromised. In
a phase II study of patients with untreated locally advanced
and metastatic NSCLC, carboplatin AUC 6 mg/ml per minute
intravenously on day 1 and vinorelbine 25 mg/m2 intrave-
nously on days 1, 8, and 15 were administered every 28 days
without growth factor support.13 Median dose intensity for
vinorelbine was 66% and reflected that fact that chemotherapy-
induced neutropenia limited day 15 vinorelbine administra-
tion to only 18% of patients.
Our study used a 21-day cycle with carboplatin AUC 6
mg/ml per minute intravenously on day 1 and vinorelbine 30
mg/m2 intravenously on days 1 and 8 and represented a high
planned dose intensity. The administration of pegfilgrastim
on day 9 resulted in a median dose intensity of 17.2 mg/m2
per week for vinorelbine compared with a planned 20 mg/m2
per week. The delivered dose intensity of 86% in our study is
a considerable improvement from previous studies, particu-
larly in view of the every 3 weeks delivery of carboplatin.
Whether this improvement is due to an altered dosing sched-
ule for vinorelbine or the administration of pegfilgrastim is
uncertain. Although no claims of improved efficacy can be
made in this study, the 1-year survival rate of 46% and 3-year
survival rate of 20% are encouraging.
The recently reported Global Lung Oncology Branch 02
(Glob2) multicenter, international, phase III study compared
carboplatin AUC 5 mg/ml per minute intravenously on day 1
FIGURE 1. Kaplan-Meier survival curve.
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and vinorelbine 30 mg/m2 intravenously on days 1 and 8 in
advanced NSCLC, a regimen similar to the one used in our
trial, with a non–platinum-containing doublet of gemcitabine
and vinorelbine.15 Growth factor support was not allowed
(personal communication). Cycles were repeated every 3
weeks. Dose intensity for vinorelbine was 18.2 mg/m2 per
week with a relative dose intensity of 91%. Although the
median and delivered dose intensities of the Glob2 study, in
the absence of growth factor support, are comparable with
those achieved in our study, the Glob2 study experienced a
slightly higher rate of febrile neutropenia (11%) rate com-
pared with that observed in our study (7%). Lower carbopla-
tin dose and better baseline patient characteristics may
account for the ability of Glob2 to maintain dose intensity
despite the lack of growth factor support. Of note, more
than 60% of patients receiving carboplatin and vinorelbine
in Glob2 had a PS greater than 90% compared with 17% in
our study.
Optimizing chemotherapy delivery in advanced disease
may have some relevance to earlier stage disease, particularly
in the adjuvant setting. The recently reported Adjuvant Na-
velbine International Trialist Association trial explored the
effect of adjuvant cisplatin and vinorelbine compared with
observation in surgically resected patients with stage IB–IIIA
NSCLC.37 Overall survival was significantly improved at 5
years in those who received adjuvant therapy compared with
observation, with the benefit being maintained at 7 years.
Median dose intensity was greater with cisplatin (89%; range,
17–108) than with vinorelbine (59%; range, 17–100). Based
on current evidence, cisplatin is the preferred platinum agent
in the adjuvant setting; however, due to comorbidities or
intolerance, not all patients are candidates for this agent.
Our phase II study in patients with advanced NSCLC
and borderline PS found pegfilgrastim to safely and effec-
tively support a chemotherapy regimen of carboplatin and
vinorelbine, a regimen whose dose intensity is affected by
overlapping hematologic toxicities, primarily neutropenia.
Sixty-seven percent of patients experienced at least one dose
delay, dose reduction, or chemotherapy omission with non-
hematologic toxicities and other adverse events accounting
for the majority of events (60%). The administration of
pegfilgrastim minimized the incidence of febrile neutropenia
in cycle 1 and across all cycles compared with previously
published literature. Despite this, six patients were unable to
receive day 8 vinorelbine at the full dose because of neutro-
penia. This observation raises the possibility of studying
earlier administrations of myeloid growth factors to further
improve on drug delivery.
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